Final HCV Guidance Should Allow For Sample Bank Correlation Studies - HIMA
This article was originally published in The Gray Sheet
Executive Summary
The "least burdensome" approach to resolving discrepant patient information in hepatitis C assay clinical studies - allowing use of sample bank correlation studies - should be explicitly stated in FDA's final guidance, the Health Industry Manufacturers Association says in comments to FDA.